Cancer Immunotherapy in India: Engineering Precision, Persistence, and Personalization

The problems being solved

Cancer immunotherapy in India is moving beyond broad activation to address a set of interlinked biological barriers. The first is precise recognition: tumors express a shifting landscape of antigens like Nectin-4, BCMA, ROR1, and KRAS mutants, but healthy tissues often share similar markers. Innovators are designing molecules that discriminate with high avidity, targeting not just one but multiple antigens simultaneously to prevent escape.

Immune checkpoint suppression remains a formidable wall. Tumors exploit checkpoints such as CD73, NKG2A, PD-L1, LAG-3, and CD47 to silence attacking T cells and natural killer cells. The problem is not merely blocking one pathway but doing so without triggering systemic autoimmunity, and many current inhibitors still leave room for resistance.

A third challenge is persistence: even when T cells are activated, they quickly become exhausted within the hostile tumor microenvironment. The microenvironment itself actively recruits suppressive cells like M2 macrophages and regulatory T cells while releasing cytokines such as IL-38 that dampen immune responses. Overcoming this requires not just stronger effector cells but a fundamental reprogramming of the local milieu.

Finally, there is the need for personalization. Every tumor harbors a unique set of mutations, and off-the-shelf therapies often miss private neoantigens. Indian research is tackling the complexity of identifying patient-specific epitopes and delivering them in a way that generates durable, adaptive immunity.

• Targeting tumor-specific and tumor-associated antigens with high precision to avoid on-target, off-tumor toxicity.
• Breaking multiple immune checkpoint pathways simultaneously while preserving self-tolerance.
• Engineering T cells and NK cells that resist exhaustion and persist long-term in solid tumors.
• Reprogramming the immunosuppressive tumor microenvironment by depleting M2 macrophages and blocking inhibitory cytokines.
• Designing personalized neoantigen vaccines and adaptive dosing regimens tailored to individual mutational profiles.

How the field is solving it

Indian innovators are deploying a diverse toolkit that spans antibody engineering, cell therapy, small molecules, and computational design. In antibody engineering, the focus is on bispecific and hybrid constructs that can engage two targets at once—for example, bridging a tumor antigen and a T cell receptor, or simultaneously blocking a checkpoint while delivering a costimulatory signal. Humanized and single-domain antibodies are being developed to reduce immunogenicity and improve tumor penetration.

Cell-based therapies are being reimagined for solid tumors. CAR-T cells are no longer simple antigen receptors; they now incorporate advanced signaling domains from 4-1BB and CD137, secrete engineered cytokines like IL-7-CCL19 to remodel the microenvironment, and are designed as dual-targeting systems to prevent antigen escape. T cell receptor engineering is pushing the boundaries of multi-allele recognition, allowing the same therapy to work across diverse patient populations.

Small molecule immunomodulators are emerging as a complementary strategy. Inhibitors of CD73 and DGKζ, along with STING and TLR7 agonists, are being formulated to activate innate immunity directly within the tumor. These molecules can be delivered in nanoparticle or micelle formulations that improve bioavailability and reduce systemic side effects.

At the intersection of computation and biology, AI-optimized nanoparticle design is enabling precise delivery of immunomodulators and neoantigens. Machine learning models are being used to predict the most immunogenic epitopes from a patient’s tumor, guiding the creation of truly personalized vaccines. This computational layer is also helping to optimize dosing schedules that balance efficacy with toxicity.

• Bispecific antibodies and immunoconjugates that engage multiple immune pathways in a single molecule.
• CAR-T and TCR-engineered cells with built-in cytokine secretion and costimulatory domains for solid tumor persistence.
• Small molecule agonists and inhibitors that awaken innate immunity or relieve checkpoint suppression without antibody-related limitations.
• AI-driven design of nanoparticles and neoantigen selection for personalized, adaptive immunotherapy.

Where the market is heading

Globally, cancer immunotherapy is a substantial and fast-moving market. Grand View Research estimates the worldwide market at roughly USD 150–160 billion in 2025, expanding at a compound annual growth rate in the high single digits through the early 2030s. Monoclonal antibodies continue to dominate, holding over three-fifths of the product share, while lung cancer remains the leading application segment.

Several shifts are shaping the opportunity. Combination therapy regimens are becoming the norm, as single-agent approaches rarely achieve durable responses. Next-generation checkpoint inhibitors targeting LAG-3, TIGIT, and other emerging pathways are entering the pipeline. CAR-T cell therapy, long confined to hematologic cancers, is making inroads into solid tumors—a frontier where Indian innovators are particularly active.

India’s own immunotherapy landscape mirrors these global currents but with a distinct emphasis on affordability and accessibility. The country’s strengths in biomanufacturing and computational biology position it to develop cost-effective versions of complex therapies. While precise India-specific market figures are not publicly detailed, the convergence of rising cancer incidence, expanding healthcare infrastructure, and a vibrant biotech startup ecosystem suggests a growing domestic opportunity that aligns with global trends.

• Global market in the range of USD 150–160 billion in 2025, with sustained high single-digit growth (Grand View Research).
• Monoclonal antibodies remain the dominant modality; lung cancer is the leading application area.
• Combination regimens and next-generation checkpoint inhibitors are driving pipeline evolution.
• CAR-T expansion into solid tumors represents a major growth frontier, with Indian research contributing novel solutions.

The white space

Despite the progress, significant white space remains—and it is precisely where Indian innovators can make an outsized impact. Solid tumors still lack the kind of definitive cell therapy that has transformed blood cancers. The immunosuppressive microenvironment of pancreatic, glioblastoma, and triple-negative breast cancers demands entirely new strategies, perhaps combining microenvironment reprogramming with multi-specific engagers.

Personalized immunotherapy is another open field. While neoantigen vaccines have shown promise, the challenge of rapid, affordable manufacturing for each patient is unsolved. India’s expertise in generic drug production and computational biology could be harnessed to create decentralized, AI-driven manufacturing platforms that bring bespoke vaccines within reach.

Combination therapy optimization is still largely empirical. There is room for rational design of multi-modal regimens—pairing oncolytic viruses with checkpoint inhibitors, or STING agonists with CAR-T cells—guided by systems biology models. Additionally, the development of therapies that work across diverse HLA alleles, a necessity in India’s genetically varied population, remains underexplored.

Finally, the interface of immunotherapy with other modalities like targeted radionuclide therapy or microbiome modulation is nascent. Innovators who can bridge these domains may unlock synergies that neither field can achieve alone.

• Solid tumor cell therapy: overcoming the microenvironment in hard-to-treat cancers.
• Rapid, affordable manufacturing of personalized neoantigen vaccines using AI and distributed production.
• Rational combination design using systems biology to move beyond trial-and-error regimens.
• Therapies engineered for broad HLA coverage to serve India’s genetically diverse population.
• Cross-modal innovation: integrating immunotherapy with radiopharmaceuticals or microbiome science.

Explore the innovators

The specific inventors, patents, and companies driving these solutions in India are building a rich ecosystem of deep-tech innovation. From novel antibody constructs to AI-optimized cell therapies, the work is documented in a growing body of intellectual property. To discover who is working on what—and to find potential collaborators or investment opportunities—the Deeptech Navigator offers a curated window into this landscape. Dive in to see the people and ideas shaping the future of cancer care.

In our data

Sources

• Immunotherapy for Cancer ↗
• What Is Immunotherapy? ↗
• Immunotherapy for Cancer: How It Works, Benefits and ... ↗
• Delivering the Full Value Chain for Oncology Clinical Trials ↗
• Personalized Supply Chains for Cell Therapies ↗
• Who are the Top Companies in the North America Cancer ... ↗
• Cancer Immunotherapy Market Size Report, 2026-2033 ↗
• U.S. Cancer Immunotherapy Market Size, Industry Report, 2035 ↗